logo
VulnCheck Integrates with ServiceNow to Advance Vulnerability Management

VulnCheck Integrates with ServiceNow to Advance Vulnerability Management

Business Wire3 days ago

LEXINGTON, Mass.--(BUSINESS WIRE)-- VulnCheck, the exploit intelligence company, today announced the launch of VulnCheck for Vulnerability Response and VulnCheck for SBOM Response, certified ServiceNow integrations available today in the ServiceNow Store. Both new VulnCheck apps help customers minimize exploit risk with unmatched visibility and centralized oversight of the vulnerability management and supply chain lifecycles.
VulnCheck for Vulnerability Response enables enhanced, organization-wide vulnerability and exploit management to power response workflows within ServiceNow instances. VulnCheck for SBOM Response helps teams defend against software supply chain attacks that introduce open source software risk. The module embeds real-time, prioritizing exploit intelligence directly into Software Bill of Materials (SBOMs) to manage incident response workflows with speed and precision.
Unlike conventional vulnerability feeds that rely on static risk scores, VulnCheck provides dynamic insights—such as Known Exploited Vulnerabilities (KEVs), proof-of-concept exploits, and weaponization details—enabling security teams to rapidly pinpoint and remediate threats within third-party and open-source components. With these integrations, organizations are empowered to rapidly identify and remediate vulnerabilities in third-party and internal software components, significantly reducing risk exposure, accelerating incident response, and ensuring regulatory compliance.
Key benefits of VulnCheck for SBOM Response include:
Automated Vulnerability Identification: Seamless ingestion and enrichment of SBOM data with VulnCheck's extensive vulnerability database, offering real-time visibility into software supply chain risks.
Prioritized Threat Intelligence: Focused remediation efforts driven by exploit-centric intelligence that highlights vulnerabilities under active attack, reducing false positives and noise.
Streamlined Incident Response: Direct integration with ServiceNow workflows automates ticket creation and remediation tracking, accelerating response times and improving resource allocation.
Continuous Monitoring & Compliance: Ongoing SBOM hygiene and vulnerability monitoring supports compliance with Executive Order 14028 and other regulatory frameworks.
Enterprise-Grade Collaboration: Enhanced visibility and centralized oversight within ServiceNow facilitate cross-team collaboration between security, IT, and DevOps.
Key benefits of VulnCheck for Vulnerability Response include:
Dynamic Vulnerability Enrichment: Fetch and enrich vulnerabilities from the VulnCheck platform with exploit intelligence, populating ServiceNow tables automatically.
Flexible Configuration: Customized authentication, filtering, and integration settings to suit enterprise needs.
Efficient Data Management: Run daily or on-demand integrations to keep vulnerability and exploit data current.
Focused Remediation: Enrich specific vulnerabilities or sets by ID for targeted action.
Centralized Exposure Assessment: Create vulnerable item details and streamline incident response.
'With VulnCheck's real-time exploit intelligence now embedded directly into ServiceNow, organizations can act on the most critical threats faster than ever before,' said Anthony Bettini, CEO and Founder of VulnCheck. 'Our solution continuously delivers actionable, prioritized intelligence so security teams can focus on what matters most. These integrations not only streamline workflows but fundamentally advance how enterprises manage security risks to improve their overall defense posture.'
VulnCheck delivers the most comprehensive, real-time exploit and vulnerability intelligence, autonomously collected at the time of disclosure. VulnCheck sources data from nearly 500 channels and over 400 million records across all CVEs. The platform refreshes its feed every eight hours and provides data output in machine-readable formats. Designed for seamless integration into security workflows and products, VulnCheck enables product, security, and response teams to track, prioritize, and remediate the most critical vulnerabilities before attackers strike.
VulnCheck for SBOM Response and VulnCheck for Vulnerability Response are now available on the ServiceNow Store, enabling organizations to harness the power of real-time vulnerability intelligence within their existing IT and security workflows without disruption.
For more information about VulnCheck and its intelligence services, visit https://vulncheck.com/.
About VulnCheck
VulnCheck is the exploit intelligence company helping enterprises, government organizations, and cybersecurity vendors solve the vulnerability prioritization challenge. Trusted by some of the world's largest organizations responsible for protecting hundreds of millions of systems and people, VulnCheck helps organizations outpace adversaries by providing the most comprehensive, real-time vulnerability intelligence that is autonomously correlated with unique, proprietary exploit and threat intelligence. Follow the company on LinkedIn or X.
To learn more about VulnCheck, visit https://vulncheck.com/.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

EMEREN GROUP INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Emeren Group Ltd.
EMEREN GROUP INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Emeren Group Ltd.

Business Wire

time3 hours ago

  • Business Wire

EMEREN GROUP INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Emeren Group Ltd.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Emeren Group Ltd. (NYSE: SOL) to Shurya Vitra Ltd. Under the terms of the proposed transaction, shareholders of Emeren Group will receive $0.20 in cash per ordinary share or $2.00 in cash per American Depositary Share. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit

COUCHBASE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Couchbase, Inc.
COUCHBASE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Couchbase, Inc.

Business Wire

time3 hours ago

  • Business Wire

COUCHBASE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Couchbase, Inc.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Couchbase, Inc. (NasdaqGS: BASE) to Haveli Investments. Under the terms of the proposed transaction, shareholders of Couchbase will receive $24.50 in cash for each share of Couchbase that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit

OrsoBio to Present Preclinical Data on Mitochondrial Protonophore Portfolio in Models of Obesity at the American Diabetes Association's 85th Scientific Sessions
OrsoBio to Present Preclinical Data on Mitochondrial Protonophore Portfolio in Models of Obesity at the American Diabetes Association's 85th Scientific Sessions

Business Wire

time4 hours ago

  • Business Wire

OrsoBio to Present Preclinical Data on Mitochondrial Protonophore Portfolio in Models of Obesity at the American Diabetes Association's 85th Scientific Sessions

MENLO PARK, Calif.--(BUSINESS WIRE)--OrsoBio, Inc. ('OrsoBio' or 'the Company'), a clinical-stage biopharmaceutical company developing treatments for obesity and obesity-associated disorders, today announced new preclinical data being presented at the 85th Scientific Sessions of the American Diabetes Association (ADA) being held June 20-23, 2025, in Chicago, Ill. The Company will present three abstracts highlighting the efficacy of its mitochondrial protonophores to induce weight loss and provide glycemic benefits while preserving lean mass in diet-induced obese (DIO) mice. The studies demonstrate the potential of TLC-6740 and TLC-1180—as monotherapy and in combination with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide—for both the induction and maintenance of weight loss following incretin treatment. 'The mechanism of our mitochondrial protonophores to increase energy expenditure complements that of incretins to enhance and sustain weight loss and provide additive metabolic benefits,' said Mani Subramanian, MD, PhD, Chief Executive Officer of OrsoBio. 'These preclinical findings mark an important step in fulfilling our mission to develop innovative, effective, oral therapies for obesity that preserve muscle and support cardiometabolic health.' OrsoBio is advancing a pipeline of novel therapies targeting obesity through mechanistically distinct and complementary approaches. The Company's lead candidates include TLC-6740 and TLC-1180, both mitochondrial protonophores that promote weight loss by increasing energy expenditure. In addition, OrsoBio is developing TLC-3595, a selective inhibitor of acetyl-CoA carboxylase 2 (ACC2), designed to enhance fat oxidation. "GLP-1 receptor agonists have transformed obesity treatment but are limited by gastrointestinal side effects and loss of muscle mass,' said Rob Myers, MD, Chief Medical Officer of OrsoBio. 'Our preclinical data show that our mitochondrial protonophores drive sustained, fat-selective weight loss and metabolic benefits when combined with or sequenced after GLP-1 receptor agonists. These findings support our ongoing Phase 1b study of TLC-6740 in combination with tirzepatide (NCT05822544)." Poster information: Sequential Combination of the Mitochondrial Protonophore TLC-6740 With Semaglutide Normalizes Body Weight and Preserves Lean Mass in DIO Mice Abstract #1687-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT) This preclinical study assessed TLC-6740 alone, in combination with low-dose semaglutide (sequential combination), and as maintenance therapy following semaglutide discontinuation in DIO mice. The sequential combination of TLC-6740 with low-dose semaglutide produced superior body weight and fat mass loss, and improved glycemic parameters compared with TLC-6740 alone and high-dose semaglutide. Initiating TLC-6740 after semaglutide discontinuation maintained body weight and fat mass loss, and glycemic benefits. These findings support evaluation of TLC-6740 in combination with incretins in people living with obesity; a 24-week combination study of TLC-6740 with tirzepatide is ongoing (NCT05822544). De Novo or Sequential Combination of the Mitochondrial Protonophore TLC-1180 With Semaglutide Improves Weight Loss and Preserves Lean Mass in DIO Mice Abstract #1694-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT) This preclinical study evaluated the effects of TLC-1180 alone, in combination with semaglutide, and as a maintenance treatment following semaglutide discontinuation in DIO mice. As monotherapy, TLC-1180 demonstrated body weight and fat mass loss and preserved lean mass. Body weight and fat mass loss were amplified, and lean mass was preserved with TLC-1180 in combination with semaglutide. These benefits persisted when TLC-1180 was used as a maintenance treatment after semaglutide discontinuation. These data highlight the potential of TLC-1180 as monotherapy, in combination with incretins, or as maintenance therapy post incretin discontinuation in people living with obesity. Novel Combination of a Mitochondrial Protonophore and an Acetyl-CoA Carboxylase 2 (ACC2) Inhibitor Causes Weight Loss and Preserves Lean Mass in Obese Mice Abstract #1686-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT) This preclinical study evaluated the effects of the mitochondrial protonophore, TLC-1180, and the ACC2 inhibitor, TLC-3595—as monotherapy and in combination—and semaglutide in DIO mice. TLC-3595 dose dependently reduced body weight, fat mass, and liver biochemistry while preserving lean mass in DIO mice. A combination of TLC-3595 with TLC-1180 had similar weight loss efficacy to semaglutide, but preserved lean mass. Taken together, these data suggest that the novel, all-oral, non-incretin combination of TLC-3595 and TLC-1180 may cause similar weight loss to incretins and may afford additional advantages, including improved weight loss quality and/or tolerability (e.g., reduced incidence of gastrointestinal adverse events). About TLC-6740 TLC-6740 is a novel, oral, liver-targeted mitochondrial protonophore in development for the treatment of obesity and obesity-associated diseases, including diabetes and MASH. Based on active hepatic uptake and mitochondrial protonophore activity, TLC-6740 increases energy expenditure in hepatocytes, and is expected to have broad, systemic metabolic and cardiovascular benefits, including weight loss, improved insulin sensitivity, and as a treatment for MASH, and dyslipidemia. TLC-6740 is currently being evaluated in a Phase 1b clinical trial, as monotherapy and in combination with tirzepatide, in patients living with obesity (NCT05822544). About TLC-1180 TLC-1180 is a novel, potent, long-acting mitochondrial protonophore that has been shown to increase energy expenditure in mice with diet-induced obesity (DIO). In preclinical studies of DIO mice, TLC-1180 induced weight loss, improved glucose control, and enhanced the efficacy of GLP-1 receptor agonists, both as a single agent and in combination with incretins. TLC-1180 is currently completing IND-enabling studies and a first-in-human study is expected to initiate in 2025. About TLC-3595 TLC-3595 is a novel and selective ACC2 inhibitor designed to treat obesity and type 2 diabetes by increasing fatty acid oxidation (FAO), reducing ectopic lipid accumulation, and improving insulin sensitivity in skeletal muscle and liver. The compound may also have potential as a treatment for other conditions characterized by impaired FAO, including heart failure with preserved ejection fraction (HFpEF) and metabolic dysfunction-associated steatohepatitis (MASH). About OrsoBio, Inc. OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat obesity and obesity-associated disorders, including type 2 diabetes, MASH, and severe dyslipidemias. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism. For more information, please visit

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store